Cáncer de mama triple negativo, receptor de andrógeno y otros marcadores. Estrategias terapéuticas

Abstract

IntroductionTriple Negative Breast Cancer (TNBC) has dreadful prognosis. Surgery, radiotherapy and chemotherapy are the only effective therapies, since it has no target treatments. In TNBC, AR modulation has been demonstrated to inhibit cell development and increase apoptosis in vitro and in vivo. ObjectiveTo assess whether AR in TNBC is associated with a better prognosis. Material and methodsThis study is a retrospective description of a cohort of 163 TNBC patients, who underwent treatment from 2003 to 2017. Immunohistochemical determinations were examined in the surgical specimen for AR, E-cadherina and GATA3. ResultsAR positive TNBC are more differentiated and less proliferative tumors than AR negative (p < 0.05). However, this fact has not been significantly associated with better overall survival nor disease free survival. Loss of expression of GATA3 and E-cadherina has not been related to worse overall survival in our paper. ConclusionsAlthough no difference in TNBC survival related to AR expression has been observed, determination of AR may be useful in TNBC due to possibility of modulating AR as a target therapy. Future treatment options in TNBC may be the combined use of selective androgen receptor and other drugs such as Pi3K inhibitors or immunomodulators, due to the frequent pi3K mutations of AR positive TNBC and the usefulness of immunotherapy in TNBC.